A review of diffuse hemispheric glioma, H3 G34-mutant disease development, DNA repair, microenvironment, and treatments on the horizon

Cameron Crowell, Ziwen Zhu, Yingxiang Li, Maria L. Varela, Quinn Ostrom, Patrick J. Cimino, Sohil H. Patel, Suzanne J. Baker, Chetan Bettegowda, Houtan Noushmehr, Claudia L. Kleinman, Laura Canty, Gustavo Alencastro Veiga Cruzeiro, Anandani Nellan, Oren Becher, Tom B. Davidson, Dolores Hambardzumyan, Adam Green, Robert Thorne, Kelli WilsonBrett Theeler, Jason Gregory, Peter Mathen, Nadia Biassou, Sheila McThenia, Craig Erker, Robert Galvin, Ariane Soldatos, Pedro R. Lowenstein, Maria G. Castro, Sadhana Jackson

Research output: Contribution to journalArticlepeer-review

Abstract

Diffuse hemispheric glioma H3 G34-mutant is primarily diagnosed in adolescents/young adults. While molecular diagnostics have improved, cellular mechanisms that drive tumor progression and therapy resistance are poorly understood. Combining previous published studies with findings from the 2024 NIH G34-mutant symposium aid in summarizing translational and clinical updates on disease development, cellular repair processes, and the immune microenvironment. This collective work is meant to outline opportunities for treatment and prolonged survival.
Original languageAmerican English
Journalnpj Precision Oncology
Volume9
Issue number1
DOIs
StatePublished - 2025

Cite this